Avanafil: a new phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction

ISSN： 1745-509X

Source： Aging Health, Vol.6, Iss.5, 2010-10, pp. : 599-605

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male

By Brant William O Brock Gerald B Lue Tom F Gerridzen Ronald G Bella Anthony J

Aging Health, Vol. 3, Iss. 4, 2007-08 ,pp. : 527-542

Future Medicine

Access to resources Recommend Favorite

Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: Preliminary report

By Kondoh Nobuyuki Higuchi Yoshihide Maruyama Takuo Nojima Michio Yamamoto Shingo Shima Hiroki

The Aging Male, Vol. 11, Iss. 4, 2008-07 ,pp. : 167-170

Informa Healthcare

Access to resources Recommend Favorite

Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation

By Cimen Sertac Demir Omer Aslan Guven Esen Ahmet Adil

The Aging Male, Vol. 12, Iss. 2-3, 2009-06 ,pp. : 58-61

Informa Healthcare

Access to resources Recommend Favorite

Sildenafil in the treatment of erectile dysfunction

By Fenig David M McCullough Andrew

Aging Health, Vol. 3, Iss. 3, 2007-06 ,pp. : 295-303

Future Medicine

Access to resources Recommend Favorite

PEDF 5 inhibition in erectile dysfunction

The Aging Male, Vol. 7, Iss. 1, 2004-01 ,pp. : 56-59

Informa Healthcare

Access to resources Recommend Favorite